Eyenovia to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2018

NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. EYEN, a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia's Chief Executive Officer and Chief Medical Officer, will present data from the Company's PG21 study at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (AAO) 2018 taking place on Thursday, October 25, 2018 in Chicago, IL.

Details of the presentation are as follows:

Event: OIS@AAO 2018

Date: Thursday, October 25, 2018

Time: 12:05 – 12:11 PM

Location: Marriott Marquis Chicago

About Eyenovia

Eyenovia, Inc. EYEN is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenovia's pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, glaucoma and other eye diseases.

Company Contact:

Eyenovia, Inc.

John Gandolfo

Chief Financial Officer

jgandolfo@eyenoviabio.com

Investor Contact:

Tram Bui / Alexander Lobo

The Ruth Group

Phone: 646-536-7035/7037

tbui@theruthgroup.com / alobo@theruthgroup.com

Media Contact:

The Ruth Group

Kirsten Thomas

508-280-6592

kthomas@theruthgroup.com

Eyenovia Logo 311 x 109.png

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!